摘要
目的:评价螺旋断层根治性放疗联合同步化疗和/或抗EGFR单克隆抗体治疗局部晚期下咽癌的疗效及不良反应。方法:回顾性分析螺旋断层根治性放疗联合同步化疗和/或抗EGFR单克隆抗体治疗局部晚期下咽癌患者30例。下咽原发病灶及转移淋巴结根治性放疗计划剂量均为70 Gy/33 F、PTV1 60 Gy/33 F、PTV2 54 Gy/33 F。结果:47%患者发生了3~4级急性反应,未发生≥3级的晚期反应。30例患者放疗过程中除2例死于原发部位大出血,其余28例患者中位随访时间为15.5(3~41)个月,1和2年的原发病灶控制率、淋巴结控制率、远处转移控制率和生存率分别为63%和35%、84%和61%、89%和81%、8%和50%。全组患者治疗失败11例,原发病灶进展为最常见的失败原因。结论:螺旋断层放疗联合同步化疗和/或抗EGFR单克隆抗体治疗局部晚期下咽癌患者能很好地耐受,临床疗效较好。
Objective: This study aimed to evaluate the toxicity and therapeutic effect of radical helical tomotherapy (RHT) combined with concurrent chemotherapy in treating locally advanced hypopharyngeal cancer (HPC). Methods: Thirty patients with locally advanced HPC were treated by RHT combined with concurrent chemotherapy. The RHT dosage was as follows: 70 Gy/33 F was used in the pGTVnx+ pGTVnd treatment, 60 Gy/33 F in PTV1, and 54 Gy/33 F in PTV2. Early and late radiation side effects were evaluated against the rating scales of the Radiation Therapy Oncology Group of the European Organization for Research and Treatment. Results: Early side effects (i. e., grades 3 and 4 acute reactions) occurred in 47% of the 30 patients. Late side effects (i.e., grade 3 and higher) were not observed. Among the 30 patients, 2 died during radiotherapy for locoregional hemorrhea. In the other 28 patients, the median of follow-up time was 15.5 months (range = 3 - 41 months); the one- and two-year local relapse-free, lymph node metastasis-free, distant metastasis-free, and overall survival rates were 63% and 35%, 84% and 61%, 89% and 81%, as well as 58% and 50%, respectively. Treatment failed in 11 cases mainly because of progression of the primary lesion. Conclusion: RHT combined with concurrent chemotherapy for locally advanced hypopharyngeal cancer is well tolerated and rproduces satisfactory clinical outcomes.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第3期164-167,共4页
Chinese Journal of Clinical Oncology
关键词
螺旋断层放疗
下咽癌
局部晚期
根治性放疗
同步化疗
helical tomotherapy, hypopharyngeal neoplasm, locally advanced stage, radical radiotherapy, concurrent chemotherapy